US Stock Market Move | Moderna (MRNA.US) rises more than 7% as data from two new mRNA vaccines show positive results
As of the time of writing, the stock has risen by more than 7%, closing at $27.85.
On Monday, Moderna (MRNA.US) stock price rose, rising more than 7% to $27.85 as of the time of publication. On the news front, Moderna showcased its latest data on mRNA vaccine pipeline at the IDWeek 2025 conference, including clinical results of seasonal flu vaccine mRNA-1010 and combination vaccine mRNA-1018. The data showed that both vaccines were able to induce rapid and strong immune responses in adult participants, with no significant safety concerns observed.
Related Articles
Northeast: Music ecosystem giant NETEASE MUSIC (09899) benefits from rapid industry growth.
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Northeast: Music ecosystem giant NETEASE MUSIC (09899) benefits from rapid industry growth.
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
RECOMMEND
Nine Companies With Market Value Over RMB 100 Billion Awaiting, Hong Kong IPO Boom Continues Into 2026
07/02/2026
Hong Kong IPO Cornerstone Investments Surge: HKD 18.52 Billion In First Month, Up More Than 13 Times Year‑On‑Year
07/02/2026
Over 400 Companies Lined Up For Hong Kong IPOs; HKEX Says Market Can Absorb
07/02/2026
